Does antiviral therapy prevent recurrence of hepatitis B virus-related hepatocellular carcinoma after curative liver resection?

JAMA

Volumn 308, Issue 18, 2012, Pages 1922-1924

  Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA FETOPROTEIN; ANTIVIRUS AGENT; ENTECAVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; TELBIVUDINE; VIRUS DNA;

ANTIVIRAL THERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; EDITORIAL; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; METASTASIS; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT INFECTION; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

EID: 84868660129     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.12971     Document Type: Editorial

References (14)

1. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-1022.
2. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890-897.
3. Kim BK, Park JY, Kim Y, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008;28(3): 393-401.
4. Chen CJ, Yang HI, Su J, et al; REVEAL-HBVStudy Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73.
5. Chang MH, You SL, Chen CJ, et al; Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma inhepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348-1355.
6. Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther. 2011;16(6):787-795.
7. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29(3):971-975.
8. Liaw YF, Sung JJ, Chow WC, et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521-1531.
9. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.Ann Surg. 2007;245(6):831-842.
10. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132(7):458-465.
11. Li N, Lai EC, Shi J, et al. Ac omparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010;17(1):179-185.
12. Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg. 2011;146(6):675-681.
13. Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22(11):1929-1935.
14. Wu C-Y, Chen Y-J, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection [published online November 12, 2012]. JAMA. 2012;308(18):1906-1913.